<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001002</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 053</org_study_id>
    <secondary_id>11027</secondary_id>
    <nct_id>NCT00001002</nct_id>
  </id_info>
  <brief_title>A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time</brief_title>
  <official_title>Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To study the toxicity, pharmacokinetics, and antiretroviral effectiveness of combined oral&#xD;
      zidovudine (AZT) and intermittent intravenous foscarnet therapy in stable AIDS or AIDS&#xD;
      related complex (ARC) patients who have already received AZT for 8 - 52 weeks.&#xD;
&#xD;
      It is hypothesized that the maximum AZT antiretroviral effect, which occurs at 8 weeks of&#xD;
      therapy, will be enhanced by 2 weeks of foscarnet treatment, given at the same time by&#xD;
      intermittent intravenous infusion. In addition, the further lowering of serum p24 antigen&#xD;
      concentration that should occur during combined therapy might continue when oral AZT therapy&#xD;
      is continued without foscarnet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that the maximum AZT antiretroviral effect, which occurs at 8 weeks of&#xD;
      therapy, will be enhanced by 2 weeks of foscarnet treatment, given at the same time by&#xD;
      intermittent intravenous infusion. In addition, the further lowering of serum p24 antigen&#xD;
      concentration that should occur during combined therapy might continue when oral AZT therapy&#xD;
      is continued without foscarnet.&#xD;
&#xD;
      There is a 4-week prestudy monitoring period during which AZT alone is administered on an&#xD;
      outpatient basis, followed by a 2-week study period during which both intravenous foscarnet&#xD;
      and oral AZT are administered in the hospital. During the subsequent 6-month follow-up&#xD;
      period, oral AZT is administered and patients receive clinical evaluations. AZT is held for&#xD;
      48 hours on days before hospitalization and for 24 hours at the end of the hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">June 1991</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foscarnet sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Medication necessary for the patient's welfare at the discretion of the investigator.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  Received zidovudine (AZT) 200 mg every 4 hours (q4h) continuously for 8 - 16 weeks&#xD;
             without Grade 3 or higher toxicity.&#xD;
&#xD;
          -  Detectable p24 antigen in serum on at least 2 occasions during the prestudy period.&#xD;
             All serum p24 antigen concentrations measured during the prestudy period must be at&#xD;
             least twice the concentration cutoff value of the assay.&#xD;
&#xD;
          -  Capability of giving informed consent.&#xD;
&#xD;
          -  Per amendment of 890721, patients must enter the study period by September 30, 1989.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following will be excluded:&#xD;
&#xD;
          -  A history of hypersensitivity reaction to foscarnet or zidovudine (AZT).&#xD;
&#xD;
          -  History of Grade 3 or 4 toxicity with AZT.&#xD;
&#xD;
          -  Current Grade 2 or higher AZT toxicity.&#xD;
&#xD;
          -  Osteomalacia, neoplasm metastatic to bone, or other known bone disease.&#xD;
&#xD;
          -  Active opportunistic infection requiring myelosuppressive or nephrotoxic therapy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antimetabolites.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  Nephrotoxins.&#xD;
&#xD;
          -  Antiviral therapy.&#xD;
&#xD;
          -  Myelosuppressive or nephrotoxic therapy.&#xD;
&#xD;
          -  Acetaminophen.&#xD;
&#xD;
        Patients with the following will be excluded:&#xD;
&#xD;
          -  A history of hypersensitivity reaction to foscarnet or zidovudine (AZT).&#xD;
&#xD;
          -  History of Grade 3 or 4 toxicity with AZT.&#xD;
&#xD;
          -  Current Grade 2 or higher AZT toxicity.&#xD;
&#xD;
          -  Osteomalacia, neoplasm metastatic to bone, or other known bone disease.&#xD;
&#xD;
          -  Active opportunistic infection requiring myelosuppressive or nephrotoxic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacobson MA</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobsen MA, van der Horst C, Causey DM, Dehlinger M, Hafner R, Mills J. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053). J Infect Dis. 1991 Jun;163(6):1219-22. doi: 10.1093/infdis/163.6.1219.</citation>
    <PMID>1828075</PMID>
  </reference>
  <reference>
    <citation>Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992 Aug;36(8):1773-8. doi: 10.1128/AAC.36.8.1773.</citation>
    <PMID>1416864</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Foscarnet</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

